Valvular & structural heart disease
Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study
Authors' conclusion
In the MiCLASP study, patients with moderate FMR experienced significant MR reduction at 1 year, resulting in clinical and symptomatic benefits comparable to those with ≥moderate-severe FMR, suggesting that select patients with symptomatic moderate FMR can benefit from M-TEER.
Study context
- Population
- Patients with symptomatic moderate functional mitral regurgitation (FMR 2+) compared with FMR ≥3+, treated with the PASCAL systemenrolled patients, 101 FMR 2+ and 197 FMR ≥3+ analysed · FMR 322 · degenerative mitral regurgitation (MR) 163 · mixed/other 59
- Participants
- 544 patients
- Comparison
- Patients with symptomatic moderate FMR compared to those with FMR ≥3+
- FMR 2+n = 101
- FMR ≥3+n = 197
- Outcome
- MR ≤1+
- Follow-up
- 1 year
Main finding
As reported in the abstract
Further findings
New York Heart Association Class I/II · 1 year
Survival · 1 year
P = 0.176
Change, points
| Outcome | FMR 2+ | FMR ≥3+ |
|---|---|---|
| Change in the Kansas City Cardiomyopathy Questionnaire overall score · 1 year | +13.9 | +13.9 |
- New York Heart Association Class I/II: all p<0.001 vs baseline
- Change in the Kansas City Cardiomyopathy Questionnaire overall score: all p<0.001 vs baseline
Safety
Major adverse events (MAE) · 1 year
P = 0.413
Original publication
Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study. EuroIntervention. Published 4 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →